Unloxcyt Makes a Splash with 50% Response Rate in Trials

Sun Pharma’s Unloxcyt is making waves with a 50% response rate in skin cancer trials! At the ASCO Annual Meeting, they unveiled results from 64 patients that are nothing short of spectacular—27% had complete responses! Sure, 34% faced some side effects, but that’s just the heat of the kitchen. Unloxcyt is a game-changer, folks! Get ready for a revolution in skin cancer treatment!